Matthew P Doogue
Overview
Explore the profile of Matthew P Doogue including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1030
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kew B, Doogue M, McNeill R, Zhang M, Rucklidge J, Frampton C, et al.
Br J Clin Pharmacol
. 2025 Feb;
PMID: 39993734
Aims: Daily broad-spectrum micronutrients are being used by the general public and formulations are receiving research interest in mental health settings. Despite concerns about combining medicines and broad-spectrum micronutrients in...
2.
Wang M, Barclay M, Chin P, Doogue M
Intern Med J
. 2022 Dec;
53(6):917-922.
PMID: 36510392
Background: New Zealand went into lockdown March 2020 successfully eliminating the circulation of the coronavirus disease 2019 (COVID-19) virus. During lockdown there were reduced rates of respiratory infections and hospital...
3.
McNeill R, Zhang M, Epton M, Doogue M
Br J Clin Pharmacol
. 2021 Apr;
87(11):4397-4407.
PMID: 33855722
Aims: To evaluate the effect of severe chronic obstructive pulmonary disease (COPD) on drug metabolism by comparing the pharmacokinetics of patients with severe COPD with healthy volunteers and using the...
4.
Crake R, Strother M, Phillips E, Doogue M, Zhang M, Frampton C, et al.
Sci Rep
. 2021 Mar;
11(1):5648.
PMID: 33707475
Individual response to chemotherapy in patients with breast cancer is variable. Obesity and exercise are associated with better and worse outcomes, respectively, and it is known that both impact the...
5.
Falconer N, Spinewine A, Doogue M, Barras M
Ther Adv Drug Saf
. 2020 Dec;
11:2042098620975516.
PMID: 33294155
No abstract available.
6.
Gardiner S, Metcalf S, Werno A, Doogue M, Chambers S
N Z Med J
. 2020 Apr;
133(1512):22-30.
PMID: 32242175
Aims: To assess a persuasive multimodel approach to decreasing unnecessary intravenous (IV) clarithromycin use for community-acquired pneumonia (CAP) in Canterbury District Health Board (CDHB) hospitals. Methods: In December 2013, CDHB...
7.
Sinnappah K, Kuan I, Thynne T, Doogue M, Wright D
Br J Clin Pharmacol
. 2020 Feb;
86(7):1430-1443.
PMID: 32060931
The aims of this study were to characterise the population pharmacokinetics of metformin in patients receiving haemodialysis, and to determine the doses that will maintain median metformin plasma concentrations below...
8.
Chin P, Chuah Q, Crawford A, Clendon O, Drennan P, Dalrymple J, et al.
Intern Med J
. 2019 Nov;
50(10):1225-1231.
PMID: 31760677
Background: An electronic prescribing and administration (ePA) system has been progressively rolled out to Canterbury District Health Board (CDHB, Christchurch, New Zealand) public hospitals since 2014, and is currently used...
9.
Chin P, McNeill R, Lee H, Zhang M, Jensen B, Smith M, et al.
Ther Drug Monit
. 2019 Nov;
42(3):468-472.
PMID: 31688833
Background: A liquid chromatography-mass spectrometry assay to determine plasma dabigatran concentrations has been available for routine clinical use at our tertiary institutions since 2017. The aim of the study was...
10.
Polasek T, Doogue M, Thynne T
Ther Adv Drug Saf
. 2018 Jun;
9(6):287-295.
PMID: 29854390
With the increasing prevalence of type 2 diabetes mellitus (T2DM) in women of childbearing age, prescribing antidiabetic medications in first-trimester pregnancy is becoming more common. Metformin treatment during this time...